10.71
-0.66 (-5.80%)
| 前收盘价格 | 11.37 |
| 收盘价格 | 11.23 |
| 成交量 | 2,242,266 |
| 平均成交量 (3个月) | 1,672,947 |
| 市值 | 1,257,621,376 |
| 预期市盈率 (P/E Forward) | 29.24 |
| 价格/销量 (P/S) | 4.10 |
| 股市价格/股市净资产 (P/B) | 2.41 |
| 52周波幅 | |
| 利润日期 | 5 Nov 2025 |
| 营业毛利率 | -20.39% |
| 营业利益率 (TTM) | -31.40% |
| 稀释每股收益 (EPS TTM) | -0.500 |
| 季度收入增长率 (YOY) | 34.20% |
| 季度盈利增长率 (YOY) | 3,119.20% |
| 总债务/股东权益 (D/E MRQ) | 54.64% |
| 流动比率 (MRQ) | 11.93 |
| 营业现金流 (OCF TTM) | 63.55 M |
| 杠杆自由现金流 (LFCF TTM) | 33.54 M |
| 资产报酬率 (ROA TTM) | -0.07% |
| 股东权益报酬率 (ROE TTM) | -10.45% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 看涨 | 混合的 |
| Drug Manufacturers - Specialty & Generic (全球的) | 看涨 | 混合的 | |
| 股票 | Dynavax Technologies Corporatio | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 0.5 |
| 平均 | 1.75 |
|
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Small Value |
| 内部持股比例 | 0.58% |
| 机构持股比例 | 108.60% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Chicago Capital, Llc | 30 Sep 2025 | 4,308,802 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合